June 17th 2019EP. 1: Overview of Huntington Disease
June 17th 2019EP. 2: Genetic Testing and the Moral Dilemma of Testing
June 17th 2019EP. 3: Economic Burden and Education on Huntington
June 17th 2019EP. 4: Treatment Plan With Symptomatic Care and Patient Education
June 17th 2019EP. 5: Emerging Treatment Options for Huntington Disease
June 17th 2019EP. 6: Defining Rare Diseases and Orphan Drug Act
June 17th 2019EP. 7: Spinal Muscular Atrophy (SMA) and Types of SMA
June 17th 2019EP. 8: Patient Perspective and Payer Perspective of SMA
June 17th 2019EP. 9: Payer Diagnostic Criteria and Prior Authorization of SMA
June 17th 2019EP. 10: Prior Authorization and Payer Test Coverage of SMA
June 17th 2019EP. 11: Diagnostic Tests and Scales of SMA
June 17th 2019EP. 12: Economic Burden and Challenges of Trial of SMA
June 17th 2019EP. 13: Treatment Goals and Multidisciplinary Management of SMA
June 17th 2019EP. 14: Approval of Nusinersen for SMA
June 17th 2019EP. 15: ENDEAR Study, Patient Factors, and Drug Approval Criteria
June 17th 2019EP. 16: Knowledge Among Payers and Payer Requirements for Rare Disease
June 17th 2019EP. 17: Challenges of Payer Criteria and Cost of Therapy for SMA
June 17th 2019EP. 18: Payer Perspective and Value of Treatment of SMA
June 17th 2019EP. 19: Zolgensma and the START Trial for SMA
June 17th 2019EP. 20: Risdiplam and Final Thoughts
